Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis

被引:0
|
作者
Matin, Abdul [1 ,2 ]
Chaudhry, Gul-e-Saba [1 ]
Azra, Mohamad Nor [1 ]
Gazli, Mohamad [1 ,3 ]
Sung, Yeong Yik [1 ]
Muhammad, Tengku Sifzizul TENGku [1 ]
机构
[1] Univ Malaysia Terengganu, Inst Climate Adaptat & Marine Biotechnol, Kuala Nerus 21030, Terengganu, Malaysia
[2] Chattogram Vet & Anim Sci Univ, Fac Food Sci & Technol, Dept Food Proc & Engn, Chattogram, Bangladesh
[3] Univ Teuku Umar, Fac Fisheries & Marine Sci, Dept Marine Sci, West Aceh, Indonesia
来源
MALAYSIAN JOURNAL OF MEDICAL SCIENCES | 2024年 / 31卷 / 04期
关键词
atherosclerosis; bempedoic acid; PCSK9; inhibitors; lipid-lowering therapy; REDUCING LIPIDS; EFFICACY; DISEASE; SAFETY; SCOPUS;
D O I
10.21315/mjms2024.31.4.2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Atherosclerosis is characterised by the accumulation of fatty deposits and plaque as a result of a continuously high level of low-density lipoprotein cholesterol (LDL-C) in the blood. The primary objective of this research is to assess the current status of knowledge, research endeavours and developmental trajectories about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in correlation with atherosclerosis treatment. Additionally, this study aims to compile bibliometric and scientometric investigations within this domain through rigorous scientometric analysis. Analysing the bibliometric landscape and global research trends associated with PCSK9 inhibitors can contribute valuable insights into comprehending atherosclerosis. This is exemplified by examining publications within the Web of Science Core Collection (WOSCC) database from 2008 to 2022. Citespace was used for frequency, co-occurrence, co-citation, grouping and burst analysis, and Microsoft Excel was used to manage descriptive datasets. Eight hundred eighty-five publications available from WOSCC database between the years 2008 and 2022 were extracted and examined. Over the period, 3,138 collaborating institutions from 87 countries, a staggering 7,750 writers involved and 325 distinct journals published about PCSK9 inhibitors studies. Among authors, Sabatine et al. and the journal The New England Journal of Medicine has had the most significant impact. Lipid-lowering therapy and bempedoic acid are the most prominent topical clusters associated with PCSK9 inhibitors, and the most often used keywords are efficacy, safety and PCSK9 inhibitors. We believe this is the first comprehensive analysis of PCSK9 inhibitors research and publications conducted using Scientometric. These results demonstrate the nascence of PCSK9 inhibitors research. They may encourage a wide range of stakeholders, particularly early career researchers from various disciplines, to work together in the future.
引用
收藏
页码:14 / 34
页数:21
相关论文
共 50 条
  • [1] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview
    Noel, Zachary R.
    Beavers, Craig J.
    AMERICAN JOURNAL OF MEDICINE, 2017, 130 (02): : 229.e1 - 229.e4
  • [2] A short review of proprotein convertase subtilisin/kexin type 9 inhibitors
    Alali, Rudaynah A.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2019, 20 (01) : 1 - 8
  • [3] Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels
    Ye, Qian
    Svatikova, Anna
    Meeusen, Jeffrey W.
    Kludtke, Erica L.
    Kopecky, Stephen L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 128 : 163 - 167
  • [4] Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
    Julius U.
    Tselmin S.
    Schatz U.
    Fischer S.
    Bornstein S.R.
    Clinical Research in Cardiology Supplements, 2019, 14 (Suppl 1) : 45 - 50
  • [5] Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9
    Kotani, Kazuhiko
    Banach, Maciej
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : E78 - E82
  • [6] Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis
    Ferraz-Amaro, I.
    Delgado-Frias, E.
    Hernandez-Hernandez, V.
    Sanchez-Perez, H.
    de Armas-Rillo, L.
    Garcia-Dopico, J. A.
    Diaz-Gonzalez, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (03) : S18 - S24
  • [7] Statins plus ezetimibe in the era of proprotein convertase subtilisin/kexin type 9 inhibitors
    De Luca, Leonardo
    Corsini, Alberto
    Uguccioni, Massimo
    Colivicchi, Furio
    KARDIOLOGIA POLSKA, 2020, 78 (09) : 850 - 860
  • [8] Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Shahreyar, Muhammed
    Salem, Salem A.
    Nayyar, Mannu
    George, Lekha K.
    Garg, Nadish
    Koshy, Santhosh K. G.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) : 628 - 634
  • [9] Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review
    Singh, Sonia
    Sharma, Himanshu
    Ramankutty, Raghavan
    Ramaswamy, Sarada
    Agrawal, Nitin
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2023, 26 (15) : 2668 - 2678
  • [10] Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events
    Turgeon, Ricky D.
    Pearson, Glen J.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (11) : 747 - 754